Vertex Pharmaceuticals (VRTX) Income from Continuing Operations (2009 - 2026)

Vertex Pharmaceuticals (VRTX) has reported Income from Continuing Operations for 18 consecutive years, with 1031400000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 59.59% year-over-year to 1031400000.0; the TTM figure through Mar 2026 stood at 4338300000.0 (up 538.7% YoY), while the FY2025 annual figure was 3953200000.0, up 838.09% from the prior year.
• Income from Continuing Operations came in at 1031400000.0 for Q1 2026 at Vertex Pharmaceuticals, down from 1191100000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 1191100000.0 in Q4 2025, with the low at 3593600000.0 in Q2 2024.
• Average Income from Continuing Operations over 5 years is 670035294.12, with a median of 930500000.0 recorded in 2022.
• Across the five-year window, Income from Continuing Operations jumped 1109.7% in 2022 and plunged 492.44% in 2024, its largest moves.
• Year by year, Income from Continuing Operations stood at 818900000.0 in 2022, then advanced by 18.31% to 968800000.0 in 2023, then declined by 5.76% to 913000000.0 in 2024, then jumped by 30.46% to 1191100000.0 in 2025, then declined by 13.41% to 1031400000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 1031400000.0, 1191100000.0, and 1082900000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.